The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment.
10.19746/j.cnki.issn.1009-2137.2023.01.023
- Author:
Ling-Ling YIN
1
;
Yang-Ling SHEN
2
;
Feng-Ling MIN
3
;
Wei-Ying GU
2
;
Ying WANG
1
;
Kun-Ming QI
1
;
Zhen-Yu LI
1
;
Kai-Lin XU
4
,
5
Author Information
1. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
2. Department of Hematology, The Third Affiliated Hospital of Suzhou University(The First People's Hospital of Changzhou), Changzhou 213003, Jiangsu Province, China.
3. Department of Hematology, The Affiliated Hospital of Yangzhou University, Yangzhou 225009, Jiangsu Province, China.
4. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China,E-mail: limd@
5. com.
- Publication Type:Journal Article
- Keywords:
daratumumab;
efficacy;
multiple myeloma;
renal impairment
- MeSH:
Humans;
Middle Aged;
Aged;
Aged, 80 and over;
Multiple Myeloma/drug therapy*;
Retrospective Studies;
Dexamethasone/therapeutic use*;
Antibodies, Monoclonal/therapeutic use*;
Bortezomib/therapeutic use*;
Renal Insufficiency/drug therapy*;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(1):141-147
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of daratumumab in treatment of multiple myeloma (MM) patients with renal impairment (RI).
METHODS:The clinical data of 15 MM patients with RI who received daratumumab-based regimen from January 2021 to March 2022 in three centers were retrospectively analyzed. Patients were treated with daratumumab or daratumumab combined with dexamethasone or daratumumab combined with bortezomib and dexamethasone and the curative effect and survival were analyzed.
RESULTS:The median age of 15 patients was 64 (ranged 54-82) years old. Six patients were IgG-MM, 2 were IgA-MM,1 was IgD-MM and 6 were light chain MM. Median estinated glomerular filtration rate (eGFR) was 22.48 ml/(min·1.73 M2). Overall response rate of 11 patients with MM was 91% (≥MR), including 1 case of stringent complete response (sCR), 2 cases of very good partial response (VGPR), 3 cases of partial response (PR) and 4 cases of minor response (MR). The rate of renal response was 60%(9/15), including 4 cases of complete response (CR), 1 case of PR and 4 cases of MR. A median time of optimal renal response was 21 (ranged 7-56) days. With a median follow-up of 3 months, the median progression-free survival and overall survival of all patients were not reached. After treatment with daratumumab-based regimen, grade 1-2 neutropenia was the most common hematological adverse reaction. Non-hematological adverse reactions were mainly infusion-related adverse reactions and infections.
CONCLUSION:Daratumumab-based regimens have good short-term efficacy and safety in the treatment of multiple myeloma patients with renal impairment.
